Loading...
OTCM
UNVC
Market cap6mUSD
Dec 05, Last price  
0.00USD
1D
4.17%
1Q
0.00%
Name

Univec Inc

Chart & Performance

D1W1MN
OTCM:UNVC chart
P/E
P/S
171.37
EPS
Div Yield, %
Shrs. gr., 5y
16.43%
Rev. gr., 5y
20.47%
Revenues
37k
+74.91%
500,0002,428,5391,846,9493,344,5593,078,1513,905,0502,887,51016,133,65219,448,38881,39821,45714,50814,50853,68033,16521,04436,808
Net income
-1m
L-52.32%
-1,400,000-1,172,453-1,897,206-1,158,942-2,295,683-893,780-505,082-1,545,601-4,020,536-1,889,089-1,183,067-1,108,296-1,166,450-1,339,745-2,666,076-2,597,090-1,238,245
CFO
-55k
L-0.19%
-1,200,000-2,285,003-1,125,764-443,744-284,531-133,732-276,243-326,146-747,984-319,482-574,36100-3,982,299-1,770,479-55,108-55,005

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Univec, Inc., through its subsidiaries, produces, licenses, and markets medical products in the United States and internationally. It primarily provides auto-disable and safety syringes. The company offers 1 cc AD-syringe for aspirating and non-aspirating applications, which are used for dispensing dosages of allergy, immunization, and insulin medicines. It also manufactures and markets sliding sheath syringes that are designed to protect patients and healthcare workers from needle stick injuries; and bifurcated needle safety syringes, which are used in administering smallpox vaccines in response to bio-terrorist threats. Univec markets its auto-disable syringes and sliding sheath safety syringes to private hospitals, health facilities, and distributors in the United States, as well as to governments of developing countries. In addition, it assists pharmaceutical companies in marketing, fulfillment, and tracking drug samples via an online system connecting pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.
IPO date
Apr 24, 1997
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT